Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Fanapt Net Product Sales (Full Year 2024 ... future growth in their psychiatry portfolio. Vanda Pharmaceuticals Inc (NASDAQ:VNDA) launched PONVORY for the treatment of multiple sclerosis ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs, has been navigating a complex landscape of ...

Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt ® net product sales of $ ... 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ...

PONVORY Net Product Sales (Q4 2024): $6.5 million. Net Loss (Q4 2024): $4.9 million compared to a net loss of $2.4 million in Q4 2023. Operating Expenses (Q4 2024): $63.5 million, up from $52.4 ...

WASHINGTON, DC – Today, Vanda Pharmaceuticals ... PONVORY in additional indications. These developments are part of Vanda's strategy to counter challenges and drive growth through new product ...

Vanda Pharmaceuticals Inc. (NASDAQ ... VNDA's current product lineup is anchored by Fanapt, PONVORY, and HETLIOZ. Fanapt, in particular, has shown promising signs in its adoption for Bipolar ...